Navigation Links
Nature Medicine study shows Peregrine's bavituximab can cure lethal virus infections
Date:11/23/2008

TUSTIN, Calif., November 23, 2008 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) today reported publication of data in Nature Medicine that supports the broad anti-viral potential of the company's novel anti-phosphatidylserine (anti-PS) antibody platform, showing that its PS-targeting drug bavituximab can cure lethal virus infections in animal disease models.

Bavituximab is in clinical trials for the treatment of hepatitis C virus (HCV) infection and in preclinical development for the treatment of viral hemorrhagic fevers under a contract worth up to $44.4 million with the bioterrorism program of the U.S. Defense Threat Reduction Agency (DTRA). Bavituximab and other anti-PS antibodies are also being studied preclinically in HIV, cytomegalovirus (CMV) and other serious viral infections.

"Based on these findings, anti-PS antibodies such as bavituximab may represent a completely new class of drugs for the treatment of life-threatening viral infections," said study co-author Dr. Philip Thorpe, professor of pharmacology at UT Southwestern Medical Center and a scientific advisor to Peregrine. "By targeting a property of the host cell rather than the virus itself, anti-PS antibodies have the potential to treat a range of viral infections, and they should be less susceptible to the viral mutations that contribute to the development of drug resistance."

In the research reported today, scientists at UT Southwestern assessed the activity of bavituximab in animal models of two lethal viruses--cytomegalovirus and Lassa fever virus, a hemorrhagic fever virus that is listed as a class A bioterrorism agent by the CDC. Bavituximab showed potent anti-viral activity in both models.

Dr. Melina Soares, lead study author and UT Southwestern instructor of pharmacology, commented, "Recent non-affiliated research has further confirmed that exposed PS has immunosuppressive properties and is also clarifying its involvement during vi
'/>"/>

Contact: Barbara Lindheim
blindheim@biocompartners.com
212-918-4650
BioCom Partners
Source:Eurekalert

3

GOOD

Page: 1 2 3

Related biology news :

1. Nature study demonstrates that bacterial clotting depends on clustering
2. Extreme nature helps scientists design nano materials
3. Sirtris review of sirtuin therapeutics for diseases of aging in Nature Reviews Drug Discovery
4. Cancer signatures uncovered
5. Nature publishes new evidence about the deep biosphere written by biogeoscientists
6. Dartmouth researchers discover gene signatures for scleroderma
7. Scattered nature of Wisconsins woodlands could complicate forests response to climate change
8. Giving nature a helping hand
9. A molecular switch turns on the flame in natures blowtorch
10. Male seahorses are natures Mr. Mom, Texas A&M researchers say
11. Nature paper describes technique for extracting hierarchical structure of networks

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)...-- Genencor, a division of Danisco, has won the na...n Institute of Chemical Engineers (AIChE) for its ... ethanol. Yesterday, Robert Davis, Chair of the AI...n Steele, who is Marketing Director, Biomass Enzym...n Kelley, who is Senior Engineer, Biomass Applicat...
(Date:11/8/2009)...rdue University have discovered a new approach for...uries using nano-spheres that could be injected in...nthetic "copolymer micelles" are drug-delivery sph...00 times smaller than the diameter of a red blood ...liver drugs for cancer treatment and other therapi...
(Date:11/6/2009)...y with their arboreal hosts. But new research sugg...s of choice, the ants can get destructive to neigh...ovember issue of the American Naturalist , is the... and it reopens a centuries-old debate on the rela...tain species of plants and trees have cozy relatio...
Breaking Biology News(10 mins):Genencor Wins The American Institute of Chemical Engineers (AIChE) Sustainable Energy Award For Accellerase(R) Cellulosic Ethanol Enzymes 2Findings show nanomedicine promising for treating spinal cord injuries 2Findings show nanomedicine promising for treating spinal cord injuries 3Ants are friendly to some trees, but not others 2Biomimetic engineering design can replace spaghetti tangle of nanotubes in novel material 12400 1Biomimetic engineering design can replace spaghetti tangle of nanotubes in novel material 12400 2Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions 4509 1Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions 4509 2Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions 4509 3Streamwood Hospital Opens New Childrens Center to Meet Vital Community Need 47557 1Streamwood Hospital Opens New Childrens Center to Meet Vital Community Need 47557 2
...The legacy of nuclear weapons and nuclear energy d...ozens of sites across the United States and many m...e uranium is transported through ground water as u...um immobilization in contaminated ground water and...ic molecules known as electron donors to stimulate...
...in the UK and funded by the UK Biotechnology and B... a new drug discovery tool to identify a new playe...nding could spark a completely new class of drugs ...is week in Nature Chemical Biology researchers a...askatchewan graduate Dr Grant Churchill, explain h...
...ed an algorithm that meshes existing data to produ...respond to stimuli. Using this new method, Whitehe...logy scientists have analyzed alpha-synuclein toxi...t cell survival. Misfolded copies of the alpha-syn...rkinson,s disease. , RELEVANCE: Until now, data o...
Other Biology News:Patience pays off with methanol for uranium bioremediation 2Canadian scientist mines drugs database for new diabetes treatment 2Calculating gene and protein connections in a Parkinson's disease model 2Calculating gene and protein connections in a Parkinson's disease model 3Calculating gene and protein connections in a Parkinson's disease model 4
(Date:11/6/2009)... The agenda for Arrowhead’s 2010 Personaliz...to take place on February 22-24, 2010 in Philadelp...nce we will highlight key issues in forming partne... experiences. , Minneapol...Arrowhead’s 2010 Personalized Medicine Part...
(Date:11/5/2009)... Nov. 5 The endangered black-foote... U.S. This rare carnivore feeds on prairie dogs. ...and often entire population die-offs in towns occu... implemented a ferret breeding program and has bee...rmerly native habitat. Unfortunately, plague can ...
(Date:11/5/2009)...lif., Nov. 5 ThermoGenes...nnovative products for processing and storing adul... quarter of fiscal 2010. ,, For the quarter end...es of $5.2 million, a 15 percent increase over rev...ago. The Company said the key contributors to the ...
(Date:11/5/2009)...v. 5 BioSpecifics Techno... company developing first-in-class collagenase-bas... for the third quarter ended September 30, 2009. ...of this year, the FDA,s Arthritis Advisory Committ... approval of XIAFLEX(TM) for the treatment of Dupu...
Breaking Biology Technology:Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 3Colorado Companies Team Up With U.S. Fish & Wildlife Service to Protect Black-Footed Ferret 2ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 2ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 3ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 4ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 5ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 6ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 7ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 8BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5
... Biotech Products, L. P. Supports Program to Recog...o recognize the,extraordinary commitment of oncolo...ounced its support of CURE magazine,s 2008 Extraor...nors one of the thousands of,exceptional oncology ...cation, compassion and helpfulness. Last year, mor...
...ands the Company,s Clinical Stage Product Portfoli...uticals,Inc. today announced that it is has comple...and commercialize products under AstraZeneca,s IP ...tors (AI) in combination with,estrogen and progest...Meditrina,s clinical stage product portfolio which...
...ERSBURG, Md., Feb. 6 Iomai Corporation,(Nasdaq: ...ompany,s,president and chief executive officer, wi...onference in New York City on Tuesday, Feb. 12. Mr... Time in the in New Amsterdam,Suite of the Waldorf...ate and clinical milestones and,detail the results...
Other Biology Technology:Call for Entries - 2008 CURE Extraordinary Healer Award for Oncology Nursing 2Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca 2Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca 3Iomai CEO to Speak at BIO CEO & Investor Forum on Feb. 12 2
Mouse Anti-20S Proteasome alpha1, 2, 3, 5, 6, & 7-Subunits Monoclonal Antibody, Unconjugated, Clone MCP231 from Calbiochem
...een the 500 l and 4 ml centrifugal concentrators. ...spin products with low internal surface and membra...olutions. ,Available with a choice of PES, Cell...highest flexibility for process optimisation. ,A...
Mouse Anti-HSV-2 Glycoprotein G-2 Monoclonal Antibody, Unconjugated, Clone H1206 from Meridian Life Science, Inc.
...Region By immunoblotting the antibody reacts again...free MMP-2 or MMP-2 bound to TIMP-2. affinity isol... Solution in 0.01 M phosphate buffered saline, pH ...e. synthetic peptide corresponding to the hinge re...
Biology Products: